Wolverine blend: structure, nomenclature and handling

The first component is BPC-157, a fifteen-residue peptide with a molecular weight of approximately 1,419 daltons. Its sequence corresponds to a stretch of a protein found in gastric juice, and it is made by standard solid-phase synthesis rather than expressed. The composition is unremarkable by peptide standards — no cysteine, no methionine, no tryptophan — which makes it one of the more chemically robust sequences in the catalogue.

The second component is TB-500, and here the naming requires care. That research code is applied across the catalogue literature to two related but distinct entities: the full-length 43-residue polypeptide thymosin beta-4, weighing roughly 4,900 daltons, and the synthetic acetylated heptapeptide LKKTETQ corresponding to its actin-binding motif, weighing roughly 890. The two are separated unambiguously by mass, and the certificate rather than the label is the document that settles which one a given batch contains.

The blend is catalogued under the name Wolverine and, descriptively, as a BPC-157 and TB-500 blend. Neither is a systematic chemical name; both are trade shorthand for the pairing.

The components carry their own names. BPC-157 appears as BPC157, body protection compound-157 and PL-14736, and in sequence notation as the fifteen-residue chain. TB-500 appears as TB500, thymosin beta-4 and Tβ4, with thymosin beta-4 itself catalogued under CAS 77591-33-4 and the acetylated fragment listed separately.

Both components are typically isolated as acetate salts, which affects the mass weighed out without altering identity. Each component is also stocked individually at HEEZ, so the blend is a purchasing decision rather than a chemically distinct product.

A blend has to be characterized component by component, which is where a two-peptide vial differs from the single-compound case.

Mass spectrometry should return two intact masses, each matching the theoretical figure for its own molecule. One correct mass on a blend certificate leaves the other component unverified — and for this particular pairing, the second mass is doing double duty, because it also resolves which of the two TB-500 entities is present. The masses involved sit far apart, so the reading is unambiguous once taken.

High-performance liquid chromatography likewise resolves two main peaks rather than one, so purity is reported as a figure for each component. A single percentage attributed to the vial as a whole is less informative than it appears, because it does not say how the material divides between the two peptides.

The ratio is the third quantity: this product is supplied at 5 mg of each component, and confirming that split is a chromatographic question rather than something a label can establish. Unusually for a blend, the split is published rather than proprietary — an even division stated on the listing.

HEEZ Research supplies this blend in one format: a lyophilized vial containing 5 mg of each component, 10 mg of peptide in total. There is no second configuration in the current catalogue.

The material is supplied as a lyophilized powder. Freeze-drying removes water and leaves both peptides as a solid, markedly more stable than either in solution, and stable enough at ambient temperature to ship without refrigeration in transit.

Molar quantities differ between the components even at equal mass, because they differ in molecular weight — and by how much depends on which TB-500 entity the batch contains. Where a protocol is expressed in molar terms, that is the point at which the identity question stops being academic.

Reconstitution converts the dried cake into a working solution, and it is a standard laboratory step rather than a product specification. Which solvent is used, and at what final concentration, is determined by the protocol in force at the receiving facility.

What HEEZ specifies is the contents of the vial: this two-component lyophilized blend at 5 mg plus 5 mg, stated on the label and on the batch certificate of analysis. Where a protocol is expressed in molar rather than mass terms, the additional figures it needs are the two molecular weights, which the certificate records for the batch supplied.

One property of blends is worth noting: once reconstituted, the two peptides cannot be separated by any ordinary bench operation. A blend is a decision made at the point of purchase rather than at the point of use, which is the practical difference between buying two single-compound vials and buying one combined vial.

Sealed lyophilized material is ambient-stable for the duration of transit, so no cold chain or insulated packaging is required for shipping. On receipt the vial goes to refrigeration and is kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify, and repeated freeze-thaw cycling is avoided. Solutions are treated as short-lived relative to the lyophilized form.

Both components are comparatively undemanding by composition — neither carries cysteine or methionine, so the common oxidation routes do not apply. Where they differ is size: a 43-residue chain, if that is the entity supplied, presents considerably more surface for aggregation under mechanical stress than a fifteen-residue one. In a blend the more sensitive of the two components governs how the vial is handled.

The certificate records what an independent facility measured for one specific batch. Its value lies in being batch-specific, so the first check is that the lot number on the document matches the vial in hand.

For a blend, the second check is that both components appear. The identity section should compare an observed mass against theory for each, and the figure for the second component tells you whether the batch carries the full-length polypeptide or the heptapeptide fragment — information the product name does not carry.

The purity figures are HPLC main-peak areas as percentages of total peak area, with the attached chromatogram showing how they were arrived at. On a blend trace, two well-resolved main peaks are the expected picture.

Peptide content, or net peptide content, is sometimes reported separately. It accounts for counter-ions and residual water, and it is the figure determining how much actual peptide the nominal 5 mg of each component represents.